These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31447275)

  • 1. The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.
    Liu B; Bai M; Wang Y; Wang D; Zhao J; Li L; Dong R; Sun S
    Eur J Intern Med; 2019 Nov; 69():32-41. PubMed ID: 31447275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Once-Weekly versus Twice-Weekly Bortezomib in Patients with Hematologic Malignancies: A Meta-analysis with Trial Sequential Analysis.
    Hu B; Zhou Q; Hu YY; Zhuang L; Yi LP; Cao JX; Li TQ; Wang J
    Pharmacotherapy; 2019 Jun; 39(6):697-708. PubMed ID: 30985015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
    Kastritis E; Leleu X; Arnulf B; Zamagni E; Cibeira MT; Kwok F; Mollee P; Hájek R; Moreau P; Jaccard A; Schönland SO; Filshie R; Nicolas-Virelizier E; Augustson B; Mateos MV; Wechalekar A; Hachulla E; Milani P; Dimopoulos MA; Fermand JP; Foli A; Gavriatopoulou M; Klersy C; Palumbo A; Sonneveld P; Johnsen HE; Merlini G; Palladini G
    J Clin Oncol; 2020 Oct; 38(28):3252-3260. PubMed ID: 32730181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
    Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
    Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
    Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
    Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacist's review of the treatment of systemic light chain amyloidosis.
    Hughes DM; Staron A; Sanchorawala V
    J Oncol Pharm Pract; 2021 Jan; 27(1):187-198. PubMed ID: 33028132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis.
    Jiang F; Chen J; Liu H; Li L; Lu W; Fu R
    Indian J Hematol Blood Transfus; 2018 Apr; 34(2):216-226. PubMed ID: 29622862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
    Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
    Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
    Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions.
    Alsomali D; Mohty D; Grogan M; Dispenzieri A; Aljurf M; Kumar S; Gertz MA; Hanbali A; Hashmi SK
    Clin Adv Hematol Oncol; 2022 Oct; 20(10):609-618. PubMed ID: 36206073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen.
    Dumas B; Yameen H; Sarosiek S; Sloan JM; Sanchorawala V
    Amyloid; 2020 Dec; 27(4):244-249. PubMed ID: 32551974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
    Chen W; Ren G; Zuo K; Huang X
    Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis.
    Brennan X; Withers B; Jabbour A; Milliken S; Kotlyar E; Fay K; Ma D; Muthiah K; Hamad N; Dodds A; Bart N; Keogh A; Hayward C; Macdonald P; Moore J
    Intern Med J; 2022 Oct; 52(10):1826-1830. PubMed ID: 36266066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characterization and outcomes of a cohort of colombian patients with AL Amyloidosis.
    Lacouture Fierro JA; Ribero Vargas DA; Sánchez Cano J; Gaviria Jaramillo LM; Perilla Suarez OG; Galvez Cárdenas KM; Ospina Ospina S
    Colomb Med (Cali); 2023; 54(3):e2025667. PubMed ID: 38107838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Cardiac Light-Chain Amyloidosis in the Era of Novel Therapy　- A Single-Center Cohort Study of 227 Patients.
    Feng J; Zhang C; Shen K; Sun J; Fang Q; Zhang L; Cao X; Zhou D; Li J; Tian Z
    Circ J; 2019 Mar; 83(4):775-782. PubMed ID: 30773521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment strategy for immunoglobulin light chain amyloidosis].
    Fuchida SI
    Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016.
    Rutten KHG; Raymakers RAP; Hazenberg BPC; Nienhuis HLA; Vellenga E; Minnema MC
    Amyloid; 2018 Dec; 25(4):227-233. PubMed ID: 30513220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
    Sidana S; Narkhede M; Elson P; Hastings D; Faiman B; Valent J; Samaras C; Hamilton K; Liu HK; Smith MR; Reu FJ
    PLoS One; 2017; 12(3):e0172996. PubMed ID: 28278302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
    Balsman E
    J Oncol Pharm Pract; 2017 Oct; 23(7):545-548. PubMed ID: 27357815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.